C-Reactive Protein and Risk of Breast Cancer
- 5 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 99 (11), 890-894
- https://doi.org/10.1093/jnci/djk202
Abstract
Chronic inflammation is hypothesized to be associated with breast cancer development. However, data evaluating the association between C-reactive protein (CRP), a marker of systemic inflammation, and breast cancer risk are sparse. In the Women's Health Study, 27,919 apparently healthy women aged 45 years and older who were free of cancer and cardiovascular disease had plasma CRP levels measured at baseline. During a mean of 10 years of follow-up, a total of 892 women developed invasive breast cancer. All statistical tests were two-sided. Baseline plasma CRP level was not statistically significantly associated with breast cancer risk (highest versus lowest quintile of CRP, multivariable hazard ratio = 0.90, 95% confidence interval = 0.71 to 1.16; P(trend) = .19; crude incidence rates: 273 versus 305 per 100,000 person-years). Our data suggest that baseline plasma CRP levels are not associated with the increased risk of breast cancer in apparently healthy women.Keywords
This publication has 36 references indexed in Scilit:
- C-Reactive Protein Levels, Variation in the C-Reactive Protein Gene, and Cancer Risk: The Rotterdam StudyJournal of Clinical Oncology, 2006
- Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from GreeceCancer Epidemiology, Biomarkers & Prevention, 2006
- Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancerBritish Journal of Cancer, 2006
- Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition CohortCancer Epidemiology, Biomarkers & Prevention, 2005
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005
- Low-Dose Aspirin in the Primary Prevention of CancerJama-Journal Of The American Medical Association, 2005
- Nonsteroidal Anti-Inflammatory Drug Use and Breast Cancer Risk by Stage and Hormone Receptor StatusJNCI Journal of the National Cancer Institute, 2005
- Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive ProteinCirculation, 2004
- Acute-Phase Proteins and Other Systemic Responses to InflammationThe New England Journal of Medicine, 1999
- Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survivalEuropean Journal of Surgical Oncology, 1995